Acute Migraine

Midwest CEPAC

ICER will assess the comparative clinical effectiveness and value of treatments for acute migraine, including:

  • Two oral CGRP receptor antagonists, rimegepant (Biohaven) and ubrogepant (Allergan)
  • A 5-HT1f agonist lasmiditan (Eli Lilly).

All three of these agents are under FDA review with an anticipated decision in the final quarter of 2019.

Date of review: January 2020 

For questions, please contact

Associated Meetings

January 23, 2020 10am - 4pm CT

Sheraton Suites Chicago O’Hare
6501 Mannheim Road
Rosemont, IL 60018

The Midwest CEPAC will convene to review ICER's assessment of acute migraine treatments.

Key Dates

Associated Materials